Literatur
- 1
Grommes C, Preston D C, Al Kadhimi Z. et al .
Lambert-Eaton syndrome with large-cell neuroendocrine carcinoma of the lung.
Muscle Nerve.
2008;
37
786-789
- 2
Roohi F, Smith P R, Bergman M. et al .
A diagnostic and management dilemma: combined paraneoplastic myasthenia gravis and
Lambert-Eaton myasthenic syndrome presenting as acute respiratory failure.
Neurologist.
2006;
12
322-326
- 3
Wirtz P W, Willcox N, van der Slik A R. et al .
HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune
Lambert-Eaton myasthenic syndrome.
J Neuroimmunol.
2005;
159
230-237
- 4
Purroy G F, Comabella M, Raguer N. et al .
Lambert-Eaton Myasthenic syndrome associated with sarcoidosis.
J Neurol.
2005;
252
1127-1128
- 5
Truffert A, Allali G, Vokatch N. et al .
Mild clinical expression of Lambert-Eaton myasthenic syndrome in a patient with HIV
infection.
J Neurol Neurosurg Psychiatry.
2007;
78
910-911
- 6
Adams P J, Snutch T P.
Calcium channelopathies: voltage-gated calcium channels.
Subcell Biochem.
2007;
45
215-251
- 7
Wirtz P W, Sotodeh M, Nijnuis M. et al .
Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton
myasthenic syndrome.
J Neurol Neurosurg Psychiatry.
2002;
73
766-768
- 8
Rudnicki S A.
Lambert-Eaton myasthenic syndrome with pure ocular weakness.
Neurology.
2007;
68
1863-1864
- 9
Payne S, Wilkins D, Howard R.
An unusual cause of dysphagia.
J Neurol Neurosurg Psychiatry.
2005;
76
146
- 10
Odabasi Z, Demirci M, Kim D S. et al .
Postexercise facilitation of reflexes is not common in Lambert-Eaton myasthenic syndrome.
Neurology.
2002;
59
1085-1087
- 11
Wirtz P W, Wintzen A R, Verschuuren J J.
Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung
cancer.
Muscle Nerve.
2005;
32
226-229
- 12
O'Neill J H, Murray N MF, Newsom-Davis J.
The Lambert-Eaton myasthenic syndrome.
Brain.
1988;
111
577-596
- 13
Sanders D B.
Lambert-eaton myasthenic syndrome: diagnosis and treatment.
Ann N Y Acad Sci.
2003;
998
500-508
- 14
Maddison P, Newsom-Davis J, Mills K R. et al .
Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma.
Lancet.
1999;
353
117-118
- 15
Wirtz P W, Lang B, Graus F. et al .
P / Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival
in small cell lung cancer.
J Neuroimmunol.
2005;
164
161-165
- 16
Elrington G M, Murray N M, Spiro S G. et al .
Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective
survey of 150 patients.
J Neurol Neurosurg Psychiatry.
1991;
54
764-767
- 17
Wirtz P W, van Dijk J G, van Doorn P A. et al .
The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands.
Neurology.
2004;
63
397-398
- 18
Sieb J P, Dengler R, Jerusalem F.
Das nichtparaneoplastische Lambert-Eaton-Syndrom. Eine häufig übersehene Diagnose?.
Nervenarzt.
1992;
63
234-239
- 19
Shapiro B E, Preston D C.
Repetitive nerve stimulation and exercise testing.
Phys Med Rehabil Clin N Am.
2003;
14
185-206
- 20
Tim R W, Massey J M, Sanders D B.
Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment.
Neurology.
2000;
54
2176-2178
- 21
Hatanaka Y, Oh S J.
Ten-second exercise is superior to 30-second exercise for post-exercise facilitation
in diagnosing Lambert-Eaton myasthenic syndrome.
Muscle Nerve.
2008;
37
572-575
- 22
Oh S J, Kurokawa K, Claussen G C. et al .
Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome.
Muscle Nerve.
2005;
32
515-520
- 23
Oh S J, Hatanaka Y, Claussen G C. et al .
Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic
syndrome.
Muscle Nerve.
2007;
35
178-183
- 24
Baslo M B, Deymeer F, Serdaroglu P. et al .
Decrement pattern in Lambert-Eaton myasthenic syndrome is different from myasthenia
gravis.
Neuromuscul Disord.
2006;
16
454-458
- 25
Meriggioli M N, Sanders D B.
Advances in the diagnosis of neuromuscular junction disorders.
Am J Phys Med Rehabil.
2005;
84
627-638
- 26
Sanders D B.
The effect of firing rate on neuromuscular jitter in Lambert-Eaton myasthenic syndrome.
Muscle Nerve.
1992;
15
256-258
- 27
Lang B, Vincent A.
Autoantibodies to ion channels at the neuromuscular junction.
Autoimmun Rev.
2003;
2
94-100
- 28
Graus F, Lang B, Pozo-Rosich P. et al .
P / Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with
lung cancer.
Neurology.
2002;
59
764-766
- 29
Mason W P, Graus F, Lang B. et al .
Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton
myasthenic syndrome.
Brain.
1997;
120 (Pt 8)
1279-1300
- 30
Liao Y J, Safa P, Chen Y R. et al .
Anti-Ca2+ channel antibody attenuates Ca2+ currents and mimics cerebellar ataxia in
vivo.
Proc Natl Acad Sci USA.
2008;
105
2705-2710
- 31
Motomura M, Lang B, Johnston I. et al .
Incidence of serum anti-P / O-type and anti-N-type calcium channel autoantibodies
in the Lambert-Eaton myasthenic syndrome.
J Neurol Sci.
1997;
147
35-42
- 32
Sabater L, Titulaer M, Saiz A. et al .
SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.
Neurology.
2008;
70
924-928
- 33
Oh S J, Sher E.
MG and LEMS overlap syndrome: case report with electrophysiological and immunological
evidence.
Clin Neurophysiol.
2005;
116
1167-1171
- 34
Sha S J, Layzer R B.
Myasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient.
Muscle Nerve.
2007;
36
115-117
- 35
Katz J S, Wolfe G I, Bryan W W. et al .
Acetylcholine receptor antibodies in the Lambert-Eaton myasthenic syndrome.
Neurology.
1998;
50
470-475
- 36
Lennon V A.
Serologic profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic
syndrome.
Neurology.
1997;
48 (Suppl. 5)
23-27
- 37
Evoli A, Minicuci G M, Vitaliani R. et al .
Paraneoplastic diseases associated with thymoma.
J Neurol.
2007;
254
756-762
- 38
Warren N M, Bennett M, Lai M. et al .
Lambert-Eaton myasthenic syndrome associated with thymitis.
Neurology.
2005;
64
168-169
- 39
Verschuuren J J, Wirtz P W, Titulaer M J. et al .
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
Expert Opin Pharmacother.
2006;
7
1323-1336
- 40
Oh S J, Kim D S, Head T C. et al .
Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic
therapy in Lambert-Eaton myasthenic syndrome.
Muscle Nerve.
1997;
20
1146-1152
- 41
Lundh H, Nilsson O, Rosén I.
4-Aminopyridine – a new drug tested in the treatment of Eaton-Lambert syndrome.
J Neurol Neurosurg Psychiatry.
1977;
40
1109-1112
- 42
Maddison P, Newsom-Davis J.
Treatment for Lambert-Eaton myasthenic syndrome.
Cochrane Database Syst Rev.
2005;
, CD003279
- 43
Sanders D B, Massey J M, Sanders L L. et al .
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Neurology.
2000;
54
603-607
- 44
McEvoy K M, Windebank A J, Daube R. et al .
3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
N Engl J Med.
1989;
321
1567-1571
- 45
Buchwald B, Ahangari R, Weishaupt A. et al .
Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic
syndrome: their neutralization by intravenous immunoglobulins.
Muscle Nerve.
2005;
31
487-494
- 46
Bui P K, Kuczkowski K M, Moeller-Bertram T. et al .
New onset Lambert-Eaton myasthenic syndrome as an unexpected cause of delayed recovery
from general anesthesia after thyroidectomy.
Ann Fr Anesth Reanim.
2004;
23
926-927
- 47
Pichler M, Wang Z, Grabner-Weiss C. et al .
Block of P / Q-type calcium channels by therapeutic concentrations of aminoglycoside
antibiotics.
Biochemistry.
1996;
35
14 659-14 664
- 48
Schottland J R.
Ofloxacin in the Lambert-Eaton myasthenic syndrome.
Neurology.
1999;
52
435
- 49
Schneider-Gold C, Wessig C, Hopker M. et al .
Pregnancy and delivery of a healthy baby in autoimmune Lambert-Eaton myasthenic syndrome.
J Neurol.
2006;
253
1236-1237
- 50
Lecky B R.
Transient neonatal Lambert-Eaton syndrome.
J Neurol Neurosurg Psychiatry.
2006;
77
1094
- 51
Pelufo-Pellicer A, Monte-Boquet E, Roma-Sanchez E. et al .
Fetal exposure to 3,4-diaminopyridine in a pregnant woman with congenital myasthenia
syndrome.
Ann Pharmacother.
2006;
40
762-766
Prof. Dr. med. Jörn P. Sieb
Klinik für Neurologie, Geriatrie und Palliativmedizin, HANSE-Klinikum Stralsund
Große Parower Straße 47–53
18435 Stralsund
Email: j.sieb@klinikum-hst.de
